Interestingly, a previous study showed that in hepatocytes, caspase-2 activated SREBP2 by cleaving S1P and that genetic and pharmacologic inhibition of caspase-2 prevented liver steatosis and non-alcoholic steatohepatitis, which are caused by chronic inflammation, by suppressing SREBP2 activation (46). Here, CASP2 is linked to metabolic dysfunction-associated steatohepatitis.